Johnson & Johnson To Present Data Across Its Neuropsychiatry Portfolio at 2026 Psych Congress Annual Meeting
Johnson & Johnson (NYSE:JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting
Johnson & Johnson is sharing research results about medicines for brain and mental health at a big doctor conference. When a company shows a lot of new medical data, it helps doctors and investors understand if their medicines are working well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.